Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a comparative clinical study of metoprolol and carvedilol, conducted by Bispebjerg Hospital, focusing on patients with chronic heart failure and type 2 diabetes mellitus. Metoprolol is a cardioselective beta-1 adrenergic receptor antagonist, whereas carvedilol is a non-selective beta-blocker that also exhibits alpha-1 adrenergic receptor antagonism. The study (NCT00447512) evaluated the effects of these two beta-blockers on endothelial function and insulin-stimulated endothelial function. Carvedilol is hypothesized to have a more favorable effect on these parameters compared to metoprolol due to its vasodilatory and antioxidant properties, which may be particularly beneficial in patients with metabolic comorbidities like type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoprolol + carvedilol.